Maia Biotechnology, Inc.
Publicly observedChicago, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Chicago | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Maia Biotechnology, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | NPLUZJSWA853 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant9 Sept 2025Publicly observed
NIH SBIR/STTR award: Novel Telomere-Targeting Therapy for Advanced Non-Small Cell Lung Cancer
USD 770,168.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant9 Sept 2025Publicly observed
NIH SBIR/STTR award: Novel Telomere-Targeting Therapy for Advanced Non-Small Cell Lung Cancer
USD 770,168.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.